HOME >> BIOLOGY >> NEWS
Phase II study of therapeutic vaccine shows efficacy in patients with metastatic colorectal cancer

PHILADELPHIA A therapeutic cancer vaccine has shown effectiveness when given alongside chemotherapy to patients with metastatic colorectal cancer in a phase II trial, according to researchers at Oxford BioMedica (UK) Ltd. The study found that six of the 17 metastatic colorectal cancer patients in the study showed tumor shrinkage, classified as complete or partial responses following independent expert review.

The study, reported in the August 1 issue of Clinical Cancer Research, a journal of the American Association for Cancer Research, was designed to demonstrate the safety and immunogenicity of the vaccine, called modified vaccinia Ankara-encoding 5T4 (TroVax), when used alongside standard chemotherapy. The research was funded by Oxford BioMedica which is developing the vaccine in partnership with Sanofi-Aventis.

Unlike preventative vaccines, such as the human papillomavirus vaccine to prevent cervical cancer, TroVax is a therapeutic vaccine, designed to stimulate the immune systems of patients who already have cancer. The vaccine consists of an attenuated (non-disease causing) version of the vaccinia virus modified to deliver the gene for 5T4, a protein found in many tumors.

The idea is that the modified virus enters cells, produces the tumor protein and stimulates the immune system, said lead study author Richard Harrop, Ph.D., vice president of clinical immunology at Oxford BioMedica. To give a vaccine alongside chemotherapy might seem counterintuitive, since chemotherapy can weaken the immune system, but our study shows that TroVax could be complementary to standard chemotherapy, enhancing the immune response to tumors.

The target of this immuno-therapy approach is a tumor antigen called 5T4, a protein embedded within the membrane of cancer cells. The protein is rarely found in normal tissues, but is produced at high levels by a wide range of human cancers, including colorectal, renal, gastric and ovarian. The
'"/>

Contact: Greg Lester
lester@aacr.org
267-646-0554
American Association for Cancer Research
1-Aug-2007


Page: 1 2 3

Related biology news :

1. Biovest announces interim blinded data of fast-tracked pivotal Phase 3 clinical trial of BiovaxID
2. Oncolytics Biotech Inc. proceeds to initiate US Phase II sarcoma clinical trial
3. The Parkinsons Institute to conduct Phase III Clinical Trial of creatine for Parkinsons disease
4. Phase III trials of cellulose sulfate microbicide for HIV prevention closed
5. Phylonix awarded National Science Foundation Phase II SBIR for zebrafish screening
6. Kentucky first state to match federal SBIR-STTR Phase 1 and Phase 2 grants
7. Acorda announces positive Phase 3 Fampridine-SR study in people with multiple sclerosis
8. REMICADE Phase 3 data show rapid, significant, long-term psoriasis improvement
9. New Phase 3 data show potential benefits of Aranesp dosed every three weeks for CIA
10. Eisai announces Phase II data on E7389, a potential new therapy for the treatment of breast cancer
11. Centocor & Schering-Plough next generation biologic promising in Phase 2 rheumatoid arthritis trial

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/26/2020)... SOMERSET, N.J. (PRWEB) , ... August 25, 2020 ... ... technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and ... the upcoming 16th Annual PEGS Boston Virtual Conference & Expo, taking place between ...
(Date:8/21/2020)... ... August 18, 2020 , ... Sentien Biotechnologies, Inc., a ... U.S. Food and Drug Administration (FDA) has approved the company’s Investigational New Drug ... of severe COVID-19. Approval of this IND allows Sentien to initiate a Phase ...
(Date:8/21/2020)... ... August 20, 2020 , ... NDA ... , a Clinical Operations executive with expertise in clinical trial planning and feasibility, ... as an Expert Consultant. Throughout his career, Mr. Movahhed has helped design and ...
Breaking Biology News(10 mins):
(Date:7/31/2020)... SOMERSET, N.J (PRWEB) , ... July 29, 2020 ... ... editing company, and Catalent, the leading global provider of advanced delivery technologies, development, ... products, today announced that they have entered into a strategic partnership whereby Catalent ...
(Date:7/31/2020)... ... July 29, 2020 , ... ... top radiation centers in 16 countries, has reached its 20th anniversary of worldwide ... in routine use at top universities including University of Pennsylvania, University of Michigan, ...
(Date:7/22/2020)... ... ... Join experts from Reed Tech , Gary Saner, Sr. Manager, Information Solutions Life ... webinar on Thursday, August 13, 2020 at 11am EDT (4pm BST/UK). , The ... medical devices, the NMPA has departments dealing with medical device registration (pre-market approvals) and ...
(Date:7/18/2020)... ... 16, 2020 , ... “We are thrilled to deliver this new technology to ... of its kind on the market and we were pleased that the IFT jury ... traditional cultured ingredients, creating a natural way to extend the shelf life and improve ...
Breaking Biology Technology:
Cached News: